All News

Data from a phase II study of cabozantinib (XL184) in patients with advanced solid tumors show that the drug has activity in both bone and soft tissue. The study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including breast, lung, ovarian, and prostate.

Paid Subscriptions: UBM Medica Healthcare Publications PO Box 390427 Minneapolis, MN 55439 Ph: 952-844-0512 Fax: 952-844-0017 Email: oncsubs@masub.com Click here to change an address or to cancel a subscription. 

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist. Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems. Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions. ONCOLOGY serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers. Click here to view our media kit/rate card.Publisher and Sales Contacts:Amy BirnbachGroup PublisherPh: 201-984-6265Email: amy.birnbach@ubm.comSarah MifsudAccount ManagerDigital MediaPh: 203-523-7055Email: sarah.mifsud@ubm.com

A pilot mentor-to-mentor oncology nurse–led training program was developed in which volunteer former patients who have undergone brachytherapy for early stage breast cancer at UCSD were taught by the oncology nurse how to provide information and support to new patients about to undergo the procedure.

One in four Americans facing end-of-life is a veteran. Because of their traumatic experiences during combat, including experiences with death, veterans with cancer and other serious illnesses can have complex healthcare needs.

This article will present a detailed review of the body of evidence regarding the PSA assay, with reflections on the resulting future of prostate cancer screening.

Shiitake, an edible mushroom indigenous to East Asia, is cultivated worldwide for its purported health benefits

Last week, well-known Canadian blogger Derek Miller's final blog entry was posted on his site, penmachine.com. Miller, who died on May 3 at the age of 41, was diagnosed with stage IV metastatic colorectal cancer in 2007.

A study published in the journal Cancer on May 9 has now specifically examined the outcome of cancer survivorship of the gay, lesbian, and bisexual population. The study authors found that cancer outcomes differ based on sexual orientation.

On Wednesday May 4th, the Cancer Drug Development Roundtable took place at the Ohio State University Comprehensive Cancer Center. The roundtable consisted of high-level stakeholders and the topic was the co-development of two or more experimental drugs for cancer treatment.

Because there has been little empirical evidence to back up patients’ stories, chemobrain has been met with skepticism by the medical community and has been a painful puzzle for many patients who couldn’t quite put a name to what they were feeling. This cognitive impairment-characterized by loss of memory and stumbling on words, among other symptoms-has come to be known as “chemobrain” or “chemofog.”

Gail R. Wilensky, PhD, has written an editorial on the Medicare reform that was published on April 27. 2011 in the online version of the NEJM. Professor Wilensky is an ecomomist, senior fellow at Project HOPE, and serves on Congressional committees to advise Congress on payment and other Medicare-related issues.

A group of researchers at the Ohio State University Comprehensive Cancer Center (OSUCCC) has discovered that a certain type of RNA, microRNA-155, may provide the link between inflammation and cancer.

A basic science lab studying cell mobility pathways in mammalian development at the Fred Hutchinson Cancer Research Center has elucidated a mechanism by which cells migrate within the developing mammalian brain that adds to the current knowledge on the way other cell types travel within the body: The research may be relevant to understanding how cancer cells metastasize.

Many doctors are currently struggling with how to use Avastin to treat their breast cancer patients after the recent FDA ruling. If you are currently using Avastin to treat breast cancer patients, please share your thoughts on treatment options and combinations here.

Nancy E. Davidson I began practice as a medical oncologist in 1986, and like the journal ONCOLOGY, I am celebrating my 25th year in the field. Much has changed over the past two and a half decades, although the primary goal of optimizing care for the individual patient while ... Read More

Denosumab is an IgG2 monoclonal antibody that inhibits osteoclastic bone resorption (breakdown) via inhibition of RANKL (receptor activator of nuclear factor-kB ligand).

Accountable care organizations (ACOs) are legal entities that are responsible for the cost, quality, and care of a population of patients. ACOs are part of the Shared Savings Program of Medicare under the Affordable Care Act.

From the current literature

The recent Centers for Disease Control and Prevention (CDC) report carrying good news about cancer sur­vivorship is an urgent “heads up” for all of us in cancer care. The report states that between the years 1971 and 2001, the number of cancer survivors increased by more than three-fold (from 3 million to nearly 10 million).

Multiple myeloma (myeloma) is a highly treatable disease, but it remains incurable in the majority of cases. It is a heterogeneous disease with variability in its clinical presentation, treatment options, and prognosis.

Ginseng is an herb from the genus Panax of the Araliaceae family that is an important part of traditional Chinese medicine (TCM). It is termed an “adaptogen,” as it is believed to have properties that help to restore balance to the body and protect the body from physiologic stress.

English and Spanish PDFs

Register to be able to access the wonderful content on this site. Your FREE registration entitles you to a, b, c and helps earn a donation to Doctors without Borders.

“Comparative effectiveness research, ” or CER, has become a loaded term in our ongoing wrangling over healthcare policy. Often, however, what even knowledgeable people understand by CER is significantly at odds with what actual policy makers have in mind.

Kava is a plant indigenous to the Pacific Rim and the Hawaiian Islands whose root and rhizome are used to prepare a non-fermented beverage with relaxant effects that is used for social and recreational purposes.

CancerNetwork and the journal ONCOLOGY present exclusive hematology coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Follow the stories below and check back for more write-ups of the most important information to come out of this year's event.